Royalty agreements

Applicators with royalty agreements for A-R are located in Phoenix, Los Angeles, East Texas, Washington, and Rhode Island. These companies are able to meet the current levels of use competitively. These companies are shown in Table 10. 

All IAEA scientific and technical publications are protected by the terms of the Universal Copyright Convention as adopted in 1952 (Berne) and as revised in 1972 (Paris). The copyright has since been extended by the World Intellectual Property Organization (Geneva) to include electronic and virtual intellectual property. Permission to use whole or parts of texts contained in IAEA publications in printed or electronic form must be obtained and is usually subject to royalty agreements. Proposals for non-commercial reproductions and translations are welcomed and considered on a case-by-case basis. Enquiries should be addressed to the IAEA Publishing Section at ... 

ACS will not consider oral requests. A fee may be assessed, depending on your request. Generally, ACS does not grant blanket permission. However, a royalty agreement may be negotiated in certain cases. 

The most reasonable interpretation of the implications behind this royalty agreement is that Caro introduced the invention business on the lines of the arrangements earlier negotiated in England with Roberts, Dale Co., and directed towards the discovery of useful products, but without any emphasis on theoretical... 

While tax and royalty fiscal systems are common, another prevalent form of fiscal system is the Production Sharing Contract, in which the investor (e.g. oil company) enters into an agreement with the host government to explore and potentially appraise and develop an area. The investor is a contractor to the host government, who retains the title of any produced hydrocarbons. 

It is a term referring to a non-exclusive royalty-fee license given to a employer where an employee uses the employment s time and/or equipment to develop an invention. Shop-rights come into play when there is no assignment agreement. 

The development and commercialization of products with pharmaceutical and agricultural companies in the fields of human health, nutrition, crop production, and industrial products are their final objectives. Collaboration agreements with the partners entitle to committed funding, performance-based fees, and royalty payments for any products that might emerge from the collaborations. 

Even though the study I have concluded does not show such agreements, employment contracts which provide that the employee will receive a specified percentage of any royalty income derived from licensing the invention do exist. This provision is fairly common in the aerospace industry but generally nowhere else. Should the invention have substantial value and be widely licensed, the inventor could derive substantially more than the usual payment of 100 to 200. In my first survey of California inventors, only 3% of the inventors received between 500 and 5000 for the invention, and not one received more than 5000. As previously indicated, 54% received 1 or nothing. 

A. That is the way it used to be in the last century. In fact, chemists 100 years ago weren t as plentiful as they are today, and the chemist was hired by the job. Assume you ve got this job requiring explosives, and the chemist was an expert in explosives. The chemist comes in to solve the problem and he says, pay me so much to do this job and pay me so much in royalties on use of the explosive or if you license it to someone else. Usually the agreement would have some modest amount of living expense while the chemist was working on the project plus some return on the invention, sharing the benefits of the invention. If the invention were widely used, the inventor became rich, but those days are long past. 

Drug Product Time Between Agreement Date and Patent Expiration Effective Date of the License Brand-Name Prodncts Annual Net Sales in the Year Prior to the Agreement Royalties Paid by the Generic Company to the Brand-Name Company for the License Agreement... 

E 2 years, 6 months 15 months after date of agreement. Between 100 and 250 milhon The generic company s royalty pajnnent is 20% of generic company s first 15 million in net sales, 40% of net sales between 15 and 30 million and 60% of net sales greater than 30 miUion. 

F 3 years, 6 months 17 months after date of agreement. Between 100 and 250 million A royalty pajment of 7.5% of the generic company s net sales for months 21 through 15 prior to expiration of patents, 5% royalty of net sales for months 14 through 8, and 2.5% of net sales for months 7 through end of patent term. 

H 1 year, 11 months 14 months after date of agreement. Between 500 and 750 million Royalty-free license. 

The supply agreement sets forth the transfer price at which the generic company is obligated to purchase all of its requirements. The generic apphcant is required to pay a 50% royalty of the net profits from all sales of the generic product. 

NHS Trust and Site Principal Investigator shall promptly disclose to the Sponsor any and all Know How generated pursuant to this Agreement and undertake not to use such Know How other than for the purposes of this Agreement without the prior written consent of the Sponsor, such consent not to be unreasonably withheld. NHS Trust hereby grants to the Sponsor an exclusive, worldwide, irrevocable, fully paid up royalty free licence under such Know How (to the extent such Know How is not assigned pursuant to clause 9.4 above) to exploit the same for any purpose whatsoever. 

---